Cancer - Loxo Oncology, Inc

Cancer

Status:

Active, open to accrual

ClinicalTrials.gov:

NCT06400472

A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an AntibodyDrug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants with Selected Advanced Solid Tumors

Drug

LY4170156

Condition

platinum-resistant ovarian cancer endometrial cervical NSCLC< TNBC pancreatic CRC